Register
Login:
Share:
Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis Watch Now

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Glaxosmithkline Share News (GSK)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Glaxosmithkline (GSK)


Share Price: 1,555.00Bid: 1,500.00Ask: 1,560.00Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 60.00Spread as %: 4.00%Open: 1,544.00High: 0.00Low: 0.00Yesterday’s Close: 1,555.00




GlaxoSmithKline wins U.S. approval for new flu vaccine

Mon, 17th Dec 2012 16:13

Dec 17 (Reuters) - U.S. health regulators have approved a new four-strain
seasonal influenza vaccine made by GlaxoSmithKline Plc, the company said on Monday.

The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children age 3 and older and adults against flu virus subtypes A and B contained in the vaccine.

It is the first intramuscular vaccine to protect against four influenza strains. Three-strain flu vaccines currently administered help protect against the two most common A virus strains and the B strain expected to be predominant in a given year, the company said.

Since 2000, however, two B virus strains have circulated to varying degrees each season, meaning patients infected with the B virus not contained in the vaccine were not immunized.

Fluarix Quadrivalent helps protect against the two A strains and adds coverage against a second B strain, the company said.

Three-strain vaccines 'have helped protect millions of people against flu, but in six of the last 11 flu seasons, the predominant circulating influenza B strain was not the strain that public health authorities selected,' said Dr. Leonard Friedland, head of clinical development and medical affairs for Glaxo's North American vaccines program.

'Fluarix Quadrivalent will help protect individuals against both B strains and from a public-health standpoint, can help decrease the burden of disease.'

Glaxo said it will make the vaccine available in time for the 2013-14 flu season and plans to fulfill orders for its trivalent, or three-strain, vaccines. Healthcare providers traditionally order flu vaccines about a year in advance of each flu season.

Fluarix Quadrivalent is not currently approved or licensed in any country outside of the United States.





(Reporting By Toni Clarke; Editing by Maureen Bavdek) Keywords: GLAXOSMITHKLINE/VACCINE

(toni.clarke@thomsonreuters.com)(617-856-4340)(Reuters Messaging: toni.clarke.reuters.com@reuters.net)

COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.






Trade rhetoric weighs on European shares

(For a live blog on European stocks, type LIVE/ in an Eikon news window)May 17 (Reuters) - European shares dropped on Friday after three days of gains
[17 May '19 08:03]

Ex-divs to take 23.6 points off FTSE 100 on May 16

MILAN, May 13 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the lates
[13 May '19 09:55]

UK regulator investigates China's state broadcaster for airing TV confession

LONDON, May 8 (Reuters) - Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aire
[8 May '19 15:14]

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 (Reuters) - British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc i
[4 May '19 17:24]

UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study

(Adds background on market opportunity)May 2 (Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met
[2 May '19 18:41]

UPDATE 4-GSK sees shingles vaccine sales rising, as free cash flow concerns weigh

(Adds details on respiratory drugs performance)* Vaccines unit sales surge 20 percent, led by Shingrix* Shingrix sales to be "significantly" more than
[1 May '19 12:29]

UPDATE 2-Oil firms, exporters drag FTSE 100, while Sainsbury's, LSE outshine

* FTSE 100 down 0.4 pct* FTSE 250 down 0.1 pct* Oil majors, international firms weigh* Sainsbury's jumps on profit beat* Lloyds gains on hopes of more
[1 May '19 09:39]

UPDATE 2-Oil heavyweights, exporters guide FTSE 100 close to 7-month high

* FTSE 100 up 0.9 pct* FTSE 250 up 0.3 pct* Oil majors take main index higher* Oil price surge hits airlines* Softer sterling boosts exporter stocks*
[23 Apr '19 09:48]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.